Evidence map›Paper›PMID 32552774›Full record

ArticleParasites & vectors2020

Evaluation of oral fluralaner (Bravecto

Kelly Allen, Susan Little, Melissa Petersen, Jeff Gruntmeir, Anne Barrett, Brian Herrin, Lindsay Starkey, Fangshi Sun, Frank Guerino

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Parasites & vectors, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Fluralaner (BravectoParasites & vectors · 2023
    Article
  5. Article
  6. Human and Veterinary Vaccines for Lyme Disease.Current issues in molecular biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Kelly AllenDepartment of Veterinary Pathobiology, Oklahoma State University, College of Veterinary Medicine, Stillwater, Oklahoma, 74078, USA. Kelly.allen10@okstate.edu.
Susan LittleDepartment of Veterinary Pathobiology, Oklahoma State University, College of Veterinary Medicine, Stillwater, Oklahoma, 74078, USA.
Melissa PetersenMerck Animal Health, De Soto, Kansas, 66018, USA.
Jeff GruntmeirDepartment of Comparative Diagnostics and Population Medicine, University of Florida, College of Veterinary Medicine, Gainesville, Florida, 32611, USA.
Anne BarrettMerck Animal Health, Madison, New Jersey, 07940, USA.
Brian HerrinDiagnostic Medicine/Pathobiology, Kansas State University, College of Veterinary Medicine, Manhattan, Kansas, 66506, USA.
Lindsay StarkeyDepartment of Pathobiology, Auburn University, College of Veterinary Medicine, Auburn, Alabama, 36849, USA.
Fangshi SunMerck Animal Health, Madison, New Jersey, 07940, USA.
Frank GuerinoMerck Animal Health, Madison, New Jersey, 07940, USA.
Oklahoma State University · USAuburn University · USFlorida College · USKansas State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmblyomma americanum and Rhipicephalus sanguineus (sensu lato) nymphs commonly feed on and transmit pathogens to dogs (Canis familiaris). Control of immature and adult tick life stages is necessary to fully protect animals. We evaluated efficacy of oral fluralaner (Bravecto

methodsIn each experiment, 10 dogs were administered oral fluralaner chewable tablets one time on Day 0 at a targeted minimum dose of 25 mg/kg body weight and 10 dogs remained non-treated controls. Dogs were infested with two groups of 50 A. americanum nymphs and two groups of 50 R. sanguineus (s.l.) nymphs on Days -1, 6, 28, 56 and 84. At 48 h and 72 h post-infestation, nymphs were collected from dogs, assessed as live or dead, and enumerated into categories defining attachment and engorgement status. Fluralaner efficacy was determined in separate analyses against all live nymphs and against live-fed nymphs, i.e. live nymphs that were attached to dogs at the time of collection and/or were engorged. Fluralaner was considered effective when mean numbers of live ticks were reduced in fluralaner-treated dogs by ≥ 90%.

resultsFluralaner efficacy against all live and live-fed A. americanum nymphs in the first experiment was > 94% on all collection days. Efficacy against all live R. sanguineus (s.l.) nymphs in the first experiment was  > 96% on all collection days  excluding the 48 h counts for infestations on Days 28 (83.7%), 56 (82.9%) and 84 (86.7%); efficacy against live-fed R. sanguineus (s.l.) nymphs was > 95% on all 48 h/72 h count days. Fluralaner efficacy against all live A. americanum nymphs in the second experiment was > 93% on all collection days for 8 weeks excluding the 48 h count for infestation on Day 56 (87.8%); efficacy against live-fed A. americanum nymphs was > 91% on all count days for 8 weeks. Efficacy against all live R. sanguineus (s.l.) nymphs in the  second experiment was > 91% on all 72 h collection days  except for infestations on Days 28 (76.8%) and 56 (86.3%); efficacy against live-fed R. sanguineus (s.l.) nymphs was 100% on all 72 h count days.

conclusionsA single administration of oral fluralaner to dogs is effective against A. americanum and R. sanguineus (s.l.) nymphs for up to 12 weeks.

Indexed as

AcaricidesAdministration, OralAmblyommaAnimalsDog DiseasesDogsFemaleIsoxazolesMaleNymphParasite LoadRhipicephalus sanguineusTick InfestationsTreatment OutcomeA1443 compoundAcaricidesIsoxazolesAmblyomma americanumBrown dog tickInfestationIsoxazolineLone star tickRhipicephalus sanguineus (sensu lato)

Identifiers

PMID32552774
PMCPMC7302130
OpenAlexW3036674906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.